Home/Publication/AstraZeneca-CICC Fund Leads Gene-Editing Tech
AstraZeneca-CICC Fund Leads Gene-Editing Tech 

16 Sep 2025

US$ 20.00

CICC Capital Management, through its AstraZeneca-CICC Healthcare Industrial Fund, has led the over Rmb300 m (US$45 m)...

Price / article: US$20.00
OR existing subscriber
Related Publications

Kotak Alternate Asset Managers Ltd is close to reaching the target of its Kotak Yield & Growth Fund, having raised ......

Nuveen, a wholly owned subsidiary of Teachers Insurance and Annuity Association of America, or better known as TIAA ......

Connect With Us

We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.

Rest assured that your email address will not be shared, as we hate spams as much as you do.